Detalhe da pesquisa
1.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Nat Chem Biol
; 11(6): 432-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915199
2.
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Proc Natl Acad Sci U S A
; 110(19): 7922-7, 2013 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23620515
3.
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood
; 122(6): 1017-25, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23801631
4.
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
J Pharmacol Exp Ther
; 350(3): 646-56, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24993360
5.
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat Chem Biol
; 8(11): 890-6, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23023262
6.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Biopharm Drug Dispos
; 35(4): 237-52, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415392
7.
EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes.
bioRxiv
; 2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37645799
8.
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Cancer Res
; 83(23): 3956-3973, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747726
9.
Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.
ACS Med Chem Lett
; 13(7): 1137-1143, 2022 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859865
10.
Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies.
ACS Med Chem Lett
; 12(10): 1539-1545, 2021 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671445
11.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
12.
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
PLoS One
; 13(6): e0197372, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29856759
13.
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Mol Cancer Ther
; 16(11): 2586-2597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835384
14.
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.
Sci Rep
; 7(1): 17993, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29269946
15.
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
ACS Med Chem Lett
; 7(2): 134-8, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26985287
16.
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
ACS Med Chem Lett
; 6(5): 491-5, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26005520
17.
A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels.
J Biomol Screen
; 7(1): 79-85, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11897058
18.
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
PLoS One
; 9(12): e111840, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25493630
19.
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Mol Cancer Ther
; 13(4): 842-54, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24563539